BridgeMD
New treatment option for Abortion
Official title Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
ClinicalTrials.gov ID: NCT06820177
What this study is testing
What is Tranexamic Acid?
Tranexamic Acid is an investigational medicine, being studied as a potential treatment for abortion.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality and decreased blood loss at the time of birth.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only. Healthy volunteers may be eligible.
You may be able to join if
- Able to understand and sign informed consent
- Speaks English or Spanish language,
- Requesting pregnancy termination or procedural management of fetal demise - Intrauterine pregnancy, 18 weeks 0 days and 24 weeks and 0 days gestation
You likely can't join if
- History of or current thromboembolic event (deep vein thrombosis, stroke, pulmonary embolism)
- History of coagulopathy
- Anticoagulant use in the preceding five days
- Severe renal impairment
- Chorioamnionitis or sepsis
- Suspected placenta accreta spectrum
See the full eligibility criteria
- Able to understand and sign informed consent
- Speaks English or Spanish language,
- Requesting pregnancy termination or procedural management of fetal demise - Intrauterine pregnancy, 18 weeks 0 days and 24 weeks and 0 days gestation
- History of or current thromboembolic event (deep vein thrombosis, stroke, pulmonary embolism)
- History of coagulopathy
- Anticoagulant use in the preceding five days
- Severe renal impairment
- Chorioamnionitis or sepsis
- Suspected placenta accreta spectrum
- Prophylactic uterotonics other than oxytocin given (or planned to be given) at the start of the D\&E
- Known allergic reaction or hypersensitivity to TXA
The study team makes the final eligibility decision.
Where it's taking place
- San Diego, California, United States
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include San Diego, California, United States; Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.